New hope for stubborn psoriasis: drug targets scalp, nails, and more
NCT ID NCT05938361
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 24 times
Summary
This study looks at how well the drug tildrakizumab works for psoriasis in difficult areas like the scalp, nails, genitals, and palms. About 120 adults with moderate to severe psoriasis will receive the treatment and be followed for up to 52 weeks. The goal is to see if it improves these specific spots and to check for any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS PALMARIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service de Dermatologie- Hopital Saint Joseph
Paris, 75014, France
Conditions
Explore the condition pages connected to this study.